Literature DB >> 31585477

Management and Prevention of Central Venous Catheter-Related Infections in the ICU.

Niccolò Buetti1, Jean-François Timsit1,2.   

Abstract

Central venous catheter-related bloodstream infections (CR-BSI) are a frequent event in the intensive care unit (ICU) setting. In contrast to other nosocomial infections, most risk factors for CR-BSI are linked to the device and can be prevented efficiently. Rates of CR-BSI higher than 1 per 1,000 catheter days are no longer acceptable. A continuous quality improvement program is effective to reduce them. Key elements of prevention of CR-BSI are hand hygiene, avoidance of insertion of unnecessary catheters, full sterile barrier precautions at insertion, preferential use of subclavian venous insertion site, cutaneous antisepsis with 2% chlorhexidine alcoholic preparation, use of chlorhexidine-impregnated dressings, immediate replacement of moistened or detached catheter dressings, and removal of catheters as soon as possible. Audit and feedback of the process of care, infection rates, and periodic re-education of health care providers are other instrumental tools in the prevention of CR-BSI. Catheter removal is the main therapeutic intervention, especially recommended in the case of sepsis or shock. While awaiting culture results, an empiric antimicrobial treatment of CR-BSI should target gram-positive microorganism (i.e., Staphylococcus aureus) and gram-negative coverage should be based on clinical variables, patients' risk factors, and previous colonization status. While a short course of antimicrobials (7 days) is sufficient for noncomplicated CR-BSI, a longer course of 14 days should be preferred for uncomplicated S. aureus and Candida CR-BSI. In case of persisting fever or positive blood culture after 3 days despite adequate antimicrobial therapy and catheter removal, catheter-related complications (e.g., endocarditis, thrombophlebitis, septic metastasis) should be ruled out. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31585477     DOI: 10.1055/s-0039-1693705

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  5 in total

1.  Poor prognosis of patients with severe COVID-19 admitted to an infectious disease intensive care unit during the pandemic caused by the Delta variant in Japan.

Authors:  Keigo Sekihara; Takatoshi Shibasaki; Tatsuya Okamoto; Chihiro Matsumoto; Kuniaki Ito; Kana Fujimoto; Fumito Kato; Wataru Matsuda; Kentaro Kobayashi; Ryo Sasaki; Tatsuki Uemura; Akio Kimura; Haruhito Sugiyama; Norihiro Kokudo
Journal:  Glob Health Med       Date:  2022-04-30

2.  Chlorhexidine-impregnated sponge versus chlorhexidine gel dressing for short-term intravascular catheters: which one is better?

Authors:  Niccolò Buetti; Stéphane Ruckly; Carole Schwebel; Olivier Mimoz; Bertrand Souweine; Jean-Christophe Lucet; Jean-François Timsit
Journal:  Crit Care       Date:  2020-07-23       Impact factor: 9.097

3.  Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies.

Authors:  Stijn Blot; Etienne Ruppé; Stephan Harbarth; Karim Asehnoune; Garyphalia Poulakou; Charles-Edouard Luyt; Jordi Rello; Michael Klompas; Pieter Depuydt; Christian Eckmann; Ignacio Martin-Loeches; Pedro Povoa; Lila Bouadma; Jean-Francois Timsit; Jean-Ralph Zahar
Journal:  Intensive Crit Care Nurs       Date:  2022-03-03       Impact factor: 4.235

4.  Secondary bloodstream infection in critically ill patients with COVID-19.

Authors:  Junli Zhang; Peng Lan; Jun Yi; Changming Yang; Xiaoyan Gong; Huiqing Ge; Xiaoling Xu; Limin Liu; Jiancang Zhou; Fangfang Lv
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

5.  Early prophylaxis of central venous catheter-related thrombosis using 1% chlorhexidine gluconate and chlorhexidine-gel-impregnated dressings: a retrospective cohort study.

Authors:  Tomoko Yamashita; Ayako Takamori; Akira Nakagawachi; Yoshinori Tanigawa; Yohei Hamada; Yosuke Aoki; Yoshiro Sakaguchi
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.